Antiproliferative	B:C0243095
and	O
apoptotic	B:C0162638
effects	O
of	O
a	O
specific	O
anti-insulin	B:C1883036
-	I:C1883036
like	I:C1883036
growth	I:C1883036
factor	I:C1883036
I	I:C1883036
receptor	I:C1883036
single	I:C1883036
chain	I:C1883036
antibody	I:C1883036
on	O
breast	B:C1512505
cancer	I:C1512505
cells	I:C1512505
.	O

Insulin	B:C0140080
-	I:C0140080
like	I:C0140080
growth	I:C0140080
factor	I:C0140080
I	I:C0140080
receptor	I:C0140080
(	O
Insulin	B:C0140080
-	I:C0140080
like	I:C0140080
growth	I:C0140080
factor	I:C0140080
I	I:C0140080
receptor	I:C0140080
)	O
is	O
expressed	O
on	O
breast	B:C1512505
cancer	I:C1512505
cells	I:C1512505
and	O
involves	O
in	O
metastasis	B:C4255448
,	O
survival	B:C0007620
,	O
and	O
proliferation	B:C0596290
.	O

Currently	O
,	O
application	O
of	O
Insulin	B:C0140080
-	I:C0140080
like	I:C0140080
growth	I:C0140080
factor	I:C0140080
I	I:C0140080
receptor	I:C0140080
-	O
targeting	O
monoclonal	B:C0003250
antibodies	I:C0003250
(	O
monoclonal	B:C0003250
antibodies	I:C0003250
)	O
,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
drugs	B:C0013227
,	O
is	O
a	O
promising	B:C0035171
strategy	I:C0035171
for	O
breast	B:C1511300
cancer	I:C1511300
therapy	I:C1511300
.	O

Single	B:C1883036
-	I:C1883036
chain	I:C1883036
fragment	I:C1883036
variable	I:C1883036
(	I:C1883036
scFv	I:C1883036
)	I:C1883036
antibodies	I:C1883036
have	O
been	O
introduced	O
as	O
appropriate	O
tools	O
for	O
tumor	B:C0243095
-	I:C0243095
targeting	I:C0243095
purposes	I:C0243095
because	O
of	O
their	O
advantages	O
over	O
whole	B:C0003241
antibodies	I:C0003241
.	O

In	O
the	O
present	O
study	O
,	O
we	O
employed	O
a	O
naïve	B:C0751719
phage	I:C0751719
library	I:C0751719
and	O
isolated	O
scFvs	B:C1883036
against	O
a	O
specific	B:C0003316
epitope	I:C0003316
from	O
extracellular	B:C1514562
domain	I:C1514562
of	O
Insulin	B:C0140080
-	I:C0140080
like	I:C0140080
growth	I:C0140080
factor	I:C0140080
I	I:C0140080
receptor	I:C0140080
by	O
panning	O
process	O
.	O

The	O
selected	O
scFvs	B:C1883036
were	O
further	O
characterized	O
using	O
polyclonal	B:C0014441
and	O
monoclonal	B:C0014441
phage	I:C0014441
ELISA	I:C0014441
,	O
soluble	O
monoclonal	B:C0014441
ELISA	I:C0014441
,	O
and	O
colony	B:C0032520
PCR	I:C0032520
and	O
sequencing	O
.	O

Antiproliferative	B:C0243095
and	O
apoptotic	B:C0162638
effects	O
of	O
selected	O
scFv	B:C1883036
antibodies	I:C1883036
on	O
breast	B:C1512505
cancer	I:C1512505
cell	I:C1512505
lines	I:C1512505
were	O
also	O
evaluated	O
by	O
MTT	B:C2986858
and	O
Annexin	B:C0487602
V	I:C0487602
/	I:C0487602
PI	I:C0487602
assays	I:C0487602
.	O

The	O
results	O
of	O
ELISA	B:C0014441
indicated	O
specific	O
reactions	O
of	O
the	O
isolated	O
scFvs	B:C1883036
against	O
the	O
IGF	B:C0140080
-	I:C0140080
IR	I:C0140080
peptide	I:C0140080
,	O
and	O
analyses	B:C0200931
of	I:C0200931
PCR	I:C0200931
product	I:C0200931
and	O
sequencing	O
confirmed	O
the	O
presence	B:C0150312
of	O
full	O
length	O
VH	B:C1883036
and	I:C1883036
Vκ	I:C1883036
inserts	I:C1883036
.	O

Treatment	O
of	O
MCF7	B:C0596890
and	O
SKBR3	B:C1512505
cells	I:C1512505
with	O
anti-IGF	B:C1883036
-	I:C1883036
IR	I:C1883036
scFv	I:C1883036
led	O
to	O
a	O
significant	O
growth	B:C2244509
inhibition	I:C2244509
.	O

The	O
results	O
also	O
showed	O
that	O
Single	B:C1883036
-	I:C1883036
chain	I:C1883036
fragment	I:C1883036
variable	I:C1883036
treatment	O
significantly	O
augmented	O
trastuzumab	B:C0061917
growth	I:C0061917
inhibitory	I:C0061917
effects	O
on	O
SKBR3	B:C1512505
cells	I:C1512505
.	O

The	O
percentage	O
of	O
the	O
apoptotic	B:C0162638
MCF7	B:C0596890
and	O
SKBR3	B:C1512505
cells	I:C1512505
after	O
24-h	O
treatment	O
with	O
Single	B:C1883036
-	I:C1883036
chain	I:C1883036
fragment	I:C1883036
variable	I:C1883036
was	O
39	O
and	O
30.70	O
%	O
,	O
respectively	O
.	O

Twenty	O
-	O
four	O
-	O
hour	O
treatment	O
with	O
Single	B:C1883036
-	I:C1883036
chain	I:C1883036
fragment	I:C1883036
variable	I:C1883036
in	O
combination	O
with	O
trastuzumab	B:C0728747
resulted	O
in	O
44.75	O
%	O
apoptosis	B:C0162638
of	O
SKBR3	B:C1512505
cells	I:C1512505
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
that	O
the	O
targeting	B:C1159372
of	O
Insulin	B:C0140080
-	I:C0140080
like	I:C0140080
growth	I:C0140080
factor	I:C0140080
I	I:C0140080
receptor	I:C0140080
by	O
Single	B:C1883036
-	I:C1883036
chain	I:C1883036
fragment	I:C1883036
variable	I:C1883036
can	O
be	O
an	O
effective	O
strategy	O
in	O
the	O
treatment	B:C1511300
of	I:C1511300
breast	I:C1511300
cancer	I:C1511300
and	O
provide	O
further	O
evidence	O
for	O
effectiveness	O
of	O
dual	O
targeting	B:C1159372
of	O
HER2	B:C0069515
and	O
Insulin	B:C0140080
-	I:C0140080
like	I:C0140080
growth	I:C0140080
factor	I:C0140080
I	I:C0140080
receptor	I:C0140080
in	O
breast	B:C1511300
cancer	I:C1511300
therapy	I:C1511300
.	O

